Gene expression in skeletal muscle is regulated by a family of myogenic basic helix-loop-helix (bHLH) proteins. The binding of these bHLH proteins, notably MyoD and myogenin, to E-boxes in their own regulatory regions is blocked by protein kinase C (PKC)-mediated phosphorylation of a single threonine residue in their basic region. Because electrical stimulation increases PKC activity in skeletal muscle, these data have led to an attractive model suggesting that electrical activity suppresses gene expression by stimulating phosphorylation of this critical threonine residue in myogenic bHLH proteins. We show that electrical activity stimulates phosphorylation of myogenin at threonine 87 (T87) in vivo and that calmodulin-dependent kinase II (CaMKII), as well as PKC, catalyzes this reaction in vitro. We find that phosphorylation of myogenin at T87 is dispensable for skeletal muscle development. We show, however, that the decrease in myogenin (myg) expression following innervation is delayed and that the increase in expression following denervation is accelerated in mutant mice lacking phosphorylation of myogenin at T87. These data indicate that two distinct innervation-dependent mechanisms restrain myogenin activity: an inactivation mechanism mediated by phosphorylation of myogenin at T87, and a second, novel regulatory mechanism that regulates myg gene activity independently of T87 phosphorylation.
Myogenic basic helix-loop-helix (bHLH) proteins, including MyoD, myogenin, Mrf4, and Myf5, bind to E-boxes (CANNTG) in the regulatory regions of a large number of genes that are expressed in skeletal muscle and thereby stimulate their expression (4) . These bHLH proteins bind to E-boxes in their own regulatory regions, constituting a feedback network that reinforces their expression once commitment to a myogenic fate has been initiated (5, 29) . As such, mechanisms that regulate the expression or activity of myogenic bHLH proteins serve as key regulatory points in muscle differentiation (5, 19) .
Multiple posttranslational pathways have been proposed to regulate the activity of myogenic bHLH proteins (21) . For example, dimerization with bHLH proteins, such as E12 or E47, leads to the formation of transcriptionally active heterodimers, whereas dimerization with HLH proteins lacking basic regions, such as Id proteins, generates inactive dimers (1) . The phosphorylation of myogenic bHLH proteins also regulates their activity, as protein kinase A (PKA) or PKC blocks MyoD and myogenin transcriptional activity (13, 14) . Present evidence suggests that PKA-mediated inhibition requires the phosphorylation of proteins other than the myogenic bHLH proteins (13, 31) . In contrast, PKC-mediated inhibition requires the phosphorylation of a single threonine residue, T87 in myogenin and T115 in MyoD, in its basic, DNA-binding region. The phosphorylation of this threonine is necessary and sufficient to prevent DNA binding, thereby inhibiting transcription (2, 14) .
The PKC-mediated pathway has been proposed to function during development to minimize adventitious myogenic bHLH activity in myoblasts, which might otherwise initiate premature muscle differentiation (14) and, following innervation, to inactivate myogenic bHLH proteins and thereby down-regulate the expression of specific target genes, including acetylcholine receptor (AChR) genes, that depend upon bHLH activity (11, 12) . Four lines of evidence support a role for PKC and myogenin in regulating gene expression in innervated muscle. First, myofiber electrical activity suppresses the transcription of specific genes, including AChR subunit genes, in a manner that depends upon the integrity of E-boxes in their regulatory regions (3, 28) . Second, pharmacological activation of PKC represses AChR expression in denervated muscle (12) . Third, the direct electrical stimulation of denervated muscle increases nuclear PKC activity and down-regulates myg expression (9, 12) . Fourth, the level of myogenin phosphorylation is higher in electrically active than in tetrodotoxin-treated, electrically quiescent cultured myotubes (18) .
Here, we studied the role of myogenin phosphorylation in vivo. We showed that electrical activity stimulates the phosphorylation of myogenin at T87, but we found that T87 phosphorylation is nonessential for muscle development or for the decrease in gene expression that is associated with an increase in myofiber electrical activity. We observed, however, that the kinetics in the response of the myg gene to innervation is altered both during development and following denervation. Thus, although the phosphorylation of myogenin at T87 has a role in regulating myg expression following innervation, these data indicate that pathways independent of T87 phosphoryla-tion are sufficient to inactivate myg expression during development and in adult muscle.
MATERIALS AND METHODS

Surgical procedures.
Mice were anesthetized by intraperitoneal injection of ketamine (150 mg/kg of body weight) and xylazine (10 mg/kg). Lower hind limb muscles were denervated by removing an ϳ5-mm section of the sciatic nerve. Denervated gastrocnemius muscles were stimulated in situ for 30 min with a pair of platinum wires placed on top of and below the muscle; the muscles were stimulated with a train of stimuli (100 Hz for 1 s) every 60 s as described elsewhere (16) .
Generation of myg T87N mutant mice. A mouse myg 3.85-kb genomic fragment containing all three exons was a gift of E. Olson. PCR-based mutagenesis was used to convert codon 87, in exon 1, from ACA to AAC. An frt-flanked PGKneomycin resistance cassette was inserted into the unique BamHI site in intron I, and a ␤-actin-diphtheria toxin A cassette was introduced at the 3Ј end of the genomic fragment to create the targeting construct ( Fig. 2A) . Surviving electroporated 129/SV embryonic stem (ES) cells were screened by PCR and Southern blotting, which identified two ES cell lines, from 152 clones analyzed, in which the mutant myg gene had recombined with the wild-type locus (Fig. 2B) . One cell line, 2B6, was used to generate mice that were heterozygous for the myg T87Nneo allele. myg T87Nneo mice were crossed with mice carrying a hACTB::FlpE transgene to remove the frt-flanked neomycin cassette (23) .
RNase protection analysis. For the analysis of postnatal gene expression, total RNA was isolated from limb muscles with RNA-STAT (Tel-Test Inc., Friendswood, Tex.). RNase protection assays were performed essentially as described previously (25) . Duplicate or triplicate measurements were taken for each sample; the ratio of myg to GAPDH RNA or of AChR to GAPDH differed by less than 7% in the separate measurements. The probe for myg extends from nucleotide 91 to nucleotide 252 (NCBI accession number NM_031189), and the probe for the AChR ␣ subunit extends from nucleotide 795 to nucleotide 1382 (26) . The GAPDH probe was obtained from Ambion (Austin, Tex.). Hybridization mixtures contained either 5 g of total RNA, to detect glyceraldehyde-3-phosphate dehydrogenase (GAPDH), or 20 g of RNA, to detect myg or the AChR ␣ subunit. To distinguish myg RNAs encoded from the wild-type and myg T87N alleles, we generated a 330-nucleotide probe extending from nucleotide 143 to nucleotide 472 in wild-type myg; RNA from wild-type mice fully protects this probe from RNase digestion (30 min at 37°C), whereas hybridization with RNA from myg T87N/T87N mice results in two (140-and 190-nucleotide) RNase cleavage fragments.
Phosphorylation analysis. F5D, a hybridoma cell line that secretes antibodies to myogenin, was kindly provided by W. Wright (32) . Antibodies to myogenin phosphorylated at T87 were generated by immunizing rabbits with a phosphopeptide (VDRRRAApTLREK) coupled to keyhole limpet hemocyanin (Research Genetics, Huntsville, Ala.). Limb muscle tissues were homogenized on ice in 20 mM HEPES-150 mM sodium chloride-2.5 mM EDTA (pH 7.4). Following the addition of detergent (0.1% sodium dodecyl sulfate [SDS], 0.5% sodium deoxycholate, 1% Triton X-100) and after 20 min on ice, the lysates were precleared by centrifugation. Myogenin was immunoprecipitated from the lysates by overnight incubation with F5D at 4°C. CaMKII and PKC were obtained from Upstate Biotech (Lake Placid, N.Y.) and activated according to the protocols provided by the manufacturers. The plasmid encoding glutathione Stransferase (GST)-myogenin was a gift of E. Olson (6) . GST-myogenin was phosphorylated with unlabeled ATP (1 mM; 30 min at 30°C), isolated on glutathione-Sepharose beads, fractionated by SDS-polyacrylamide gel electrophoresis, and electroblotted onto nitrocellulose; the blots were probed with F5D or antibodies to myogenin phosphorylated at T87. Primary antibodies were detected by using horseradish peroxidase-conjugated secondary antibodies to mouse or rabbit immunoglobulin G (Jackson ImmunoResearch Laboratories, West Grove, Pa.). GST-myogenin was phosphorylated with [␥-32 P]ATP (0.1 M, 10 Ci), isolated on glutathione-Sepharose beads, and fractionated by SDSpolyacrylamide gel electrophoresis; the dried gel was exposed to X-ray film for several hours at room temperature.
Histochemistry. NADH reductase activity was visualized by staining frozen sections of skeletal muscle (in 1.5 mM Nitro Blue Tetrazolium-1.5 mM ␤-NADH-0.2 M Tris [pH 7.5]) for 30 min at 25°C. Sections were dehydrated and rehydrated through an acetone series before aqueous mounting was carried out. Myosin isoform expression was assessed by staining frozen sections of skeletal muscle with antibodies to type I myosin (A4.840), type II myosin (N3.36), or type IIB myosin (BF-F3). These antibodies were purchased from the American Type Culture Collection (Manassas, Va.) and the Developmental Studies Hybridoma Bank (Iowa City, Iowa).
RESULTS
Electrical activity stimulates phosphorylation of myogenin at T87. Myogenin is phosphorylated to a greater extent in spontaneously contracting cultured myotubes than in tetrodotoxin-treated, electrically inactive myotubes (18) , but the sites of phosphorylation are not known. We directly stimulated denervated adult muscle and used antibodies directed against a phospho-T87 peptide to compare the levels of myogenin T87 phosphorylation in denervated and denervated-and-stimulated skeletal muscle (Fig. 1A) . We stimulated gastrocnemius muscles that had been denervated for 2 days for 30 min in situ and measured T87 phosphorylation in denervated and denervatedand-stimulated muscles by immunoprecipitating myogenin and probing Western blots with antibodies to myogenin phosphorylated at T87. Phosphorylation of T87 increased following electrical stimulation, whereas the level of total myogenin was unchanged (Fig. 1A) . These data indicate that electrical activity stimulates the phosphorylation of myogenin at T87 in vivo.
Myogenin is phosphorylated at T87 by CaMKII or PKC. In addition to PKC, CaMKII and mitogen-activated protein ki- (17, 20, 27) . Moreover, activated CaMKII can inhibit the binding of a myogenin/E12 heterodimer to the proximal E-box in the AChR ␦-subunit gene (27) . As the amino acid sequence preceding T87 conforms to a CaMKII consensus phosphorylation site and no other CaMKII consensus sites (RXXS/T) are found in myogenin, we investigated whether CaMKII, as well as PKC, can phosphorylate T87. Using an in vitro assay with purified kinases and GST-myogenin, we found that CaMKII, like PKC, stimulates phosphorylation of T87 in vitro (Fig. 1B) . Taken together, these results demonstrate that electrical activity stimulates the phosphorylation of myogenin at T87 in vivo, which is potentially mediated by multiple calcium-regulated pathways, including PKC and CaMKII. Muscle development appears normal in myg T87N/T87N mice. To determine the role of T87 phosphorylation in vivo, we replaced the wild-type myg allele with a mutant allele in which asparagine was substituted for T87 (Fig. 2) . Because in vitro studies indicate that phosphorylation of T87 inactivates myogenin (14), we reasoned that a failure to phosphorylate T87 might confer resistance to such inactivation, leading to adventitious myogenin activity during myogenesis and elevated myogenin activity in muscle tissue from adult mice. We replaced a T with an N because prior studies revealed that limited substitutions for T87 result in the retention of DNA-binding activity and that T87N myogenin remains a potent transcriptional activator (5, 14) .
We generated homozygous mutant mice and found that myg T87N/T87N mice are healthy and fertile. We stained sections of limb muscle tissues from 7-week-old myg T87N/T87N mice and found that muscle size, as well as the diameters of individual muscle fibers, was normal (Fig. 3) . In addition, immunostaining for myosin heavy-chain isoforms demonstrated normal patterning and percentages of fiber types in the soleus and gastrocnemius muscles (Fig. 3) . These data indicate that limb muscle development appears normal in myg T87N/T87N animals. In cultured cells, the transcriptional activity of T87N myogenin is lower than that of wild-type myogenin (5, 14) . We therefore examined whether the function of T87N myogenin is also reduced in vivo. Homozygous null myg mutant mice fail to produce secondary muscle fibers and die at birth (30 and survive as adults, indicating that myg T87N/Ϫ mice express sufficient levels of active T87N myogenin to promote muscle differentiation.
Postnatal down-regulation of myg transcription is delayed in muscle tissue from myg T87N/T87N mice. myg expression peaks during late embryogenesis and decreases perinatally, presumably due to innervation (9) . We assessed whether phosphorylation of myogenin at T87 is required to down-regulate myg expression in innervated muscle by measuring myg RNA levels in postnatal mice. In wild-type mice, myg RNA levels decreased (ca. threefold) between postnatal days 0 and 12 ( Fig.  4A) (9) . myg expression also decreased postnatally in sibling on September 8, 2017 by guest http://mcb.asm.org/ myg T87N/T87N mice but remained elevated (ϳ1.5-fold) relative to that of wild-type mice at each time point examined (Fig.  4A) . Ultimately, by 7 weeks after birth, myg transcript levels in wild-type and myg T87N/T87N mice were similar (Fig. 4A) . These data indicate that a failure to phosphorylate myogenin at T87 results in a delay in myg down-regulation but that mechanisms independent of T87 phosphorylation ultimately inactivate myg expression in postnatal muscle.
Postnatal down-regulation of a myogenin target gene is unaffected in myg T87N/T87N mice. AChR subunit genes are known to require E-boxes for their expression during development (22, 24) . In addition, transgenic mice overexpressing myogenin express AChR subunit genes at higher rates than wild-type mice (10) . These findings suggest that AChR expression, like myg expression, might be greater in neonatal myg T87N/T87N mice than in wild-type siblings. We measured the levels of AChR ␣-subunit RNA in postnatal myg T87N/T87N mice and found no differences in expression between mutant and wildtype mice (Fig. 4B ). These data indicate that the modest postnatal increase in myg expression in myg T87N/T87N mice is insufficient to increase AChR expression and demonstrate that innervation-dependent suppression of AChR ␣-subunit expression does not require the phosphorylation of myogenin at T87.
Multiple innervation-dependent pathways inactivate myg expression. Our results indicate that innervation ultimately inactivates myg expression independently of T87 phosphorylation. A failure to phosphorylate myogenin at T87, however, delays the rate at which myg expression is down-regulated postnatally. These findings raised the possibility that a failure to phosphorylate myogenin at T87 might alter the kinetics in the response of myg to denervation. myg expression is low in innervated adult muscle and increases by more than 1 order of magnitude within the first day following denervation. We denervated limb muscles and measured the rate of increase in FIG. 5 . Model for two differing innervation-dependent mechanisms that inhibit myogenin. In innervated (Inn), electrically active muscle, the transient release of calcium from intracellular stores and/or the entry of extracellular calcium through voltage-activated channels increases the activity of PKC and CaMKII, resulting in the phosphorylation of Myg at T87, inhibiting Myg from binding E-boxes and activating myg transcription. Electrical activity stimulates a second inactivation pathway, which may inhibit transcription mediated by proteins that bind a MEF2 site and/or a MEF3 site in the myg regulatory region. This second inactivation pathway is rapidly lost following denervation (Den, 12 h), but myg transcription resumes only after sufficient Myg phosphorylated at T87 (Myg-T87-P) is dephosphorylated and/or adequate Myg is synthesized to activate myg transcription (Den, 24 h). In myg T87N/T87N mutant mice, once the second inactivation mechanism is no longer effective (Den, 12 h), the latent transcriptional potential of T87N myogenin is apparent and results in a premature increase in myg transcription. mice, myg expression increased more rapidly, 4.5-fold at 8 h and 6.2-fold at 16 h (Fig. 4C) . Ultimately, by 24 h after denervation, myg expression levels in myg T87N/T87N mice and wildtype siblings were similar (Fig. 4C) . At this time and thereafter, AChR expression levels were equally elevated in wild-type and myg T87N/T87N mice (Fig. 4D) . These data suggest that two differing innervation-dependent mechanisms inhibit myogenin: a mechanism that is dependent upon the phosphorylation of T87, and a second mechanism that is independent of phosphorylation of myogenin at T87 and that is lost rapidly after denervation. Our experiments indicate that within several hours after denervation, the latter inactivation mechanism is no longer effective, allowing the latent transcriptional potential of T87N myogenin to be revealed (Fig. 5) .
DISCUSSION
In vitro studies have suggested a pivotal role for the phosphorylation of myogenin at T87 in regulating muscle differentiation. We show here that phosphorylation of T87 is dispensable for myogenesis and for down-regulation of gene expression following innervation in vivo. These data indicate that additional pathways, independent of T87 phosphorylation, are sufficient to inactivate myg expression during development and in adult muscle. Nonetheless, we find that inactivation of the myg gene is delayed postnatally and that the induction following denervation is accelerated in mutant mice lacking myogenin phosphorylation at T87. These data suggest that two differing innervation-responsive pathways restrain myogenin activity: an inactivation mechanism, independent of T87 myogenin phosphorylation, that is lost rapidly after denervation and a second mechanism that is mediated through the phosphorylation of myogenin at T87 (Fig. 5) . Once the former inactivation mechanism has been removed, which appears to occur during the first hours after denervation, T87N myogenin, latent prior to denervation, is more effective than wild-type myogenin in activating myg expression.
As myogenin can bind to E-boxes in the myg promoter and stimulate transcription (8) , the T87 myogenin-independent inactivation mechanism may involve posttranslational modifications of T87N myogenin that inactivate its ability to bind DNA or to stimulate transcription. Alternatively, this inactivation mechanism may involve transcriptional repression of myg, mediated through cis-acting elements other than E-boxes (Fig. 5) . In this regard, MEF2, a MADS-box containing a transcription factor essential for muscle development (15) , binds to the myg regulatory region and stimulates myg expression (8) . Thus, mechanisms that down-regulate MEF2 activity may be sufficient to inhibit myg T87N/T87N expression (7, 33) . A failure to phosphorylate myogenin at T87 is insufficient to activate myg expression in electrically active, innervated muscle tissue. Likewise, the disruption of the other inactivation pathway(s) may be insufficient to express myg in innervated muscle, as the phosphorylation of T87 may be adequate to ensure that myg expression remains inhibited. An understanding of how the multiple pathways regulate myg expression will require insight into the nature of the other inactivation pathway(s).
